Anti-Human E-Selectin

Purified Recombinant Human CD62E (>98%)

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Blocking: This antibody shows inhibition in the U937 adhesion assay. The adhesion of human U937 cells (5 x 10⁴ cells/well) to 2 μg/mL immobilized rhE-Selectin (100 μl/well) was maximally inhibited (80 - 100%) following pre-treatment with antibody for 1 hour using 100 μl of a 50 μg/ml antibody solution per well.

Sheep Anti-Human E-Selectin recognizes Human E-Selectin. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

E-selectin, also known as CD62E is an inducible leukocyte adhesion glycoprotein specifically expressed by endothelial cells.¹ E-selectin helps initiate recruitment of circulating leukocytes to cutaneous, bone and inflamed tissues.² E-selectin is found in inflammatory skin lesions in psoriasis, contact dermatitis, and delayed- type hypersensitivity, in arthritic joints, and in heart and renal allografts undergoing rejection.³ E-selectin-targeting antibody drug conjugate has potential as a prostate cancer therapy.⁴

1. Milstone, D. et al. (2004) PNAS 101: 8005
2. Dimitroff, CJ. et al. (2009) J Visualized Experiments
3. Hirata, T. et al. (2005) J Immunol. 175: 8042
4. Vanitha, R. et al. (2003) Cancer Res. 63: 6387